Cethromycin HCl: A Differentiated Anti-Infective Asset

The proprietary hydrochloride salt of cethromycin is the molecular foundation of AliquantumRx’s CALM program, combining liver-targeted exposure, prior human safety experience, and strong intellectual property protection.

High Hepatic Exposure Supports Liver-Stage Activity

Cethromycin HCl accumulates preferentially in the liver, where dormant malaria parasites reside.

Its pharmacologic profile supports:

  • High hepatic exposure
  • Sustained tissue persistence
  • Targeted intracellular activity

Validated Mechanism with Liver Advantage

Cethromycin HCl inhibits parasite protein synthesis through apicoplast targeting — a biologically validated pathway relevant to liver-stage malaria.

Safety and Human Exposure Summary

Cethromycin free base has been administered to more than 5,000 human subjects in prior clinical development, establishing a substantial human exposure and safety database. This human exposure supports early clinical development and helps de-risk initial clinical evaluation.

Intellectual Property Protection

Cethromycin HCl is supported by composition-of-matter and solid-form intellectual property covering the hydrochloride salt and associated polymorphs, with expected patent protection extending into 2040 and beyond. This estate strengthens AliquantumRx’s ability to advance differentiated clinical development and supports long-term commercial exclusivity. Additional patent filings and development-stage protections are being pursued to further extend lifecycle management.

Photos are from PHIL/CDC

© AliquantumRX Inc. 2022. All Rights Reserved.